Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.
Ovarian Cancer
DRUG: Paclitaxel|DRUG: Carboplatin
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.